Treatment of Moderate to Severe Lateral Canthal Lines
Completed · Phase 3 · Has a placebo group
Conditions studied: Lateral Canthal Lines
In brief
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
Key facts
- Study ID
- NCT04249687
- Run by
- Galderma R&D
- People needed
- 303
- Starts
- 2020-02-10
- Expected to finish
- 2021-02-10
- Last updated by the study team
- 2023-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Male or female 18 years of age or older.
- Moderate to severe LCL at maximum smile as assessed by the Investigator.
- Moderate to severe LCL at maximum smile as assessed by the subject.
You may not qualify if…
- Previous use of any Botulinum toxin treatment in facial areas within 9 months prior to study treatment.
- Female who is pregnant, breast feeding, or intends to conceive a child during the study.
- Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.
Where it is running
- Ablon Skin Institute and Research Center — Manhattan Beach, California, United States
- Dermatology Cosmetic Laser Medical Associates — San Diego, California, United States
- Art of Skin, MD — Solana Beach, California, United States
- Siperstein Dermatology Group, PLLC — Boynton Beach, Florida, United States
- Facial Plastic Surgicenter, Ltd — Baltimore, Maryland, United States
- The Center for Dermatology, Cosmetic & Laser Surgery — Mount Kisco, New York, United States
- Rochester Dermatologic Surgery, Ltd — Victor, New York, United States
- Aesthetic Solutions, PA — Chapel Hill, North Carolina, United States
- Dr. Shannon Humphrey, Inc — Vancouver, British Columbia, Canada
- Pacific Dermaesthetics, Inc — Vancouver, British Columbia, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.